col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


168 Results       Page 1

 [1] 
Elsevier: Antiviral Research
  original article Date Title Authors   All Authors
1 [GO] 2024―Feb―24 Methyl rosmarinate is an allosteric inhibitor of SARS-cov-2 3 C L protease as a potential candidate against SARS-cov-2 infection Hongtao Li, Meng Sun, Fuzhi Lei, Jinfeng Liu, Xixiang Chen, Yaqi Li, et al. (+10)
2 [GO] 2024―Feb―20 The α-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses Maria Giulia Bigotti, Katja Klein, Esther S. Gan, Maria Anastasina, Simon Andersson, Olli Vapalahti, et al. (+9)
3 [GO] 2024―Feb―02 An adenovirus-vectored vaccine based on the N protein of feline coronavirus elicit robust protective immune responses Yuanhong Wang, Yun Liu, Junna Wang, Miao Zhang, Xiaoying Deng, Junhan Song, et al. (+4)
4 [GO] 2024―Feb―01 Therapeutic antibodies and alternative formats against SARS-CoV-2 Rahel R. Winiger, Laurent Perez
5 [GO] 2024―Jan―24 Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome Mariia S. Bogacheva, Suvi Kuivanen, Swapnil Potdar, Antti Hassinen, Sini Huuskonen, Ina Pöhner, et al. (+13)
6 [GO] 2024―Jan―24 Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains Hawa Sophia Bouzidi, Jean-Sélim Driouich, Raphaëlle Klitting, Ornéllie Bernadin, Géraldine Piorkowski, Rayane Amaral, et al. (+8)
7 [GO] 2024―Jan―19 An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity. Adi Idris, Aroon Supramaniam, Yaman Tayyar, Gabrielle Kelly, NigelA.J. McMillan, Kevin V. Morris
8 [GO] 2024―Jan―09 TXM peptides inhibit SARS-CoV-2 infection, syncytia formation, and lower inflammatory consequences Tea Govednik, Duško Lainšček, Urška Kuhar, Marva Lachish, Sandra Janežič, Malan Štrbenc, et al. (+4)
9 [GO] 2023―Dec―27 A flexible, image-based, high-throughput platform encompassing in-depth cell profiling to identify broad-spectrum coronavirus antivirals with limited off-target effects Jordi Doijen, Inha Heo, Koen Temmerman, Peter Vermeulen, Annick Diels, Steffen Jaensch, et al. (+12)
10 [GO] 2023―Dec―27 Deubiquitinase USP39 promotes SARS-CoV-2 replication by deubiquitinating and stabilizing the envelope protein Xiang Chen, Li Tian, Linran Zhang, Wenying Gao, Miao Yu, Zhaolong Li, Wenyan Zhang
11 [GO] 2023―Dec―07 Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters Metin Aksu, Priya Kumar, Thomas Güttler, Waltraud Taxer, Kathrin Gregor, Bianka Mußil, et al. (+21)
12 [GO] 2023―Dec―05 Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis Meital Zur, Thalia Peselev, Stav Yanko, Victoria Rotshild, Ilan Matok
13 [GO] 2023―Nov―30 Broad-spectrum antiviral activity of two structurally analogous CYP3A inhibitors against pathogenic human coronaviruses in vitro Lara Gallucci, James Bazire, Andrew D. Davidson, Iart Luca Shytaj
14 [GO] 2023―Nov―28 Oral delivery of a chitosan adjuvanted COVID-19 vaccine provides long-lasting and broad-spectrum protection against SARS-CoV-2 variants of concern in golden hamsters Shen Wang, Huan Cui, Cheng Zhang, Wujian Li, Weiqi Wang, Wenwen He, et al. (+6)
15 [GO] 2023―Nov―24 A phenothiazine urea derivative broadly inhibits coronavirus replication via viral protease inhibition Katrina Forrestall, Eric S. Pringle, Dane Sands, Brett A. Duguay, Brett Farewell, Tekeleselassie Woldemariam, et al. (+4)
16 [GO] 2023―Nov―21 Lung transcriptomics of K18-hACE2 mice highlights mechanisms and genes involved in the MVA-S vaccine-mediated immune response and protection against SARS-CoV-2 infection Alberto Gómez-Carballa, Guillermo Albericio, Julián Montoto-Louzao, Patricia Pérez, David Astorgano, Irene Rivero-Calle, et al. (+4)
17 [GO] 2023―Nov―19 Monoglycosylated SARS-CoV-2 receptor binding domain fused with HAstem-scaffolded protein vaccine confers broad protective immunity against SARS-CoV-2 and influenza viruses Chia-Ying Wu, Yung-Chieh Tseng, Shao-En Kao, Li-Yang Wu, Jen-Tzu Hou, Yu-Chih Yang, et al. (+2)
18 [GO] 2023―Nov―19 Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization Qiu-Yan Zhang, Hong-Qing Zhang, Ya-Nan Zhang, Zhe-Rui Zhang, Xiao-Dan Li, Meng-Chan Hao, et al. (+10)
19 [GO] 2023―Nov―08 Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry Srikanth Sadhu, Jyotsna Dandotiya, Rajdeep Dalal, Ritika Khatri, Anna Z. Mykytyn, Aashima Batra, et al. (+12)
20 [GO] 2023―Nov―08 Induction of neutralizing antibodies and mucosal IgA through intranasal immunization with the receptor binding domain of SARS-CoV-2 spike protein fused with the type IIb E. coli heat-labile enterotoxin A subunit He-Chin Hsieh, Chung-Chu Chen, Pin-Han Chou, Wen-Chun Liu, Suh-Chin Wu
21 [GO] 2023―Nov―08 A bivalent form of a RBD-specific synthetic antibody effectively neutralizes SARS-CoV-2 variants Dong-Gun Kim, Uijin Kim, In Ho Park, Bumhan Ryu, Youngki Yoo, Jeong Seok Cha, et al. (+9)
22 [GO] 2023―Nov―07 Functional assessments of SARS-CoV-2 single-round infectious particles with variant-specific spike proteins on infectivity, drug sensitivity, and antibody neutralization Wen-Chi Su, Zan-Yu Chen, Young-Sheng Chang, King-Song Jeng, Uyen Nguyen Phuong Le, Yu-Chi Chou, et al. (+8)
23 [GO] 2023―Oct―18 Synthesis, evaluation, and mechanism of 1-(4-(arylethylenylcarbonyl)phenyl)-4-carboxy-2-pyrrolidinones as potent reversible SARS-CoV-2 entry inhibitors Srinivasa Rao Palla, Chen-Wei Li, Tai-Ling Chao, Hoi-Ling Vienn Lo, Liu Jia-Jin, Max Yu-Chen Pan, et al. (+13)
24 [GO] 2023―Oct―18 ASK1 inhibitors are potential pan-antiviral drugs, which dampen replication of diverse viruses including SARS-CoV2 Wael L. Demian, Rajesh Abraham Jacob, Olga Cormier, Aisha Nazli, Matthew Melki, Akarin Asavajaru, et al. (+6)
25 [GO] 2023―Oct―06 Induction of antiviral gene expression by cyclosporine a, but not inhibition of cyclophilin a or B, contributes to its restriction of human coronavirus 229E infection in a lung epithelial cell line John E. Mamatis, Carla E. Gallardo-Flores, Ujjwal Sangwan, Trinity H. Tooley, Taylor Walsh, Che C. Colpitts
26 [GO] 2023―Sep―28 Corrigendum to ’ Sangivamycin is preferentially incorporated into viral RNA by the SARS-CoV-2 polymerase’ [Antiviral Research 218 (2023) 105716-105728/ doi: 10.1016/j.antiviral.2023.105716] Ryan P. Bennett, Yasemin Yoluç, Jason D. Salter, Alexander Ripp, Henning J. Jessen, Stefanie M. Kaiser, Harold C. Smith
27 [GO] 2023―Sep―09 Sangivamycin is preferentially incorporated into viral RNA by the SARS-CoV-2 polymerase Ryan P. Bennett, Yasemin Yoluç, Jason D. Salter, Alexander Ripp, Henning J. Jessen, Stefanie M. Kaiser, Harold C. Smith
28 [GO] 2023―Aug―09 Diketo acid inhibitors of nsp13 of SARS-CoV-2 block viral replication Angela Corona, Valentina Noemi Madia, Riccardo De Santis, Candida Manelfi, Roberta Emmolo, Davide Ialongo, et al. (+11)
29 [GO] 2023―Aug―09 PRO-2000 exhibits SARS-CoV-2 antiviral activity by interfering with spike-heparin binding Evelien Vanderlinden, Arnaud Boonen, Sam Noppen, Geert Schoofs, Maya Imbrechts, Nick Geukens, et al. (+5)
30 [GO] 2023―Jul―20 Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2 Ellen Bowden-Reid, Scott Ledger, Yuan Zhang, Francesca Di Giallonardo, Anupriya Aggarwal, Alberto Ospina Stella, et al. (+7)
31 [GO] 2023―Jul―20 Ceragenins exhibit antiviral activity against SARS-CoV-2 by increasing the expression and release of type I interferons upon activation of the host's immune response Łukasz Suprewicz, Artur Szczepański, Marzena Lenart, Ewelina Piktel, Krzysztof Fiedoruk, Emilia Barreto-Duran, et al. (+5)
32 [GO] 2023―Jul―17 Seasonal coronavirus infections trigger NLRP3 inflammasome activation in macrophages but is therapeutically targetable Yang Li, Yining Wang, Yunlong Li, Annemarie C. de Vries, Pengfei Li, Maikel P. Peppelenbosch, Qiuwei Pan
33 [GO] 2023―Jul―13 Assessment of the frequency of SARS-CoV-2 Omicron variant escape from RNA-dependent RNA polymerase inhibitors and 3C-like protease inhibitors Emi Takashita, Seiichiro Fujisaki, Hiroko Morita, Shiho Nagata, Hideka Miura, Mami Nagashima, et al. (+4)
34 [GO] 2023―Jul―11 Evaluating Z-FA-FMK, a host cathepsin L protease inhibitor, as a potent and broad-spectrum antiviral therapy against SARS-CoV-2 and related coronaviruses Ju Hwan Jeong, Jang-Hoon Choi, Beom Kyu Kim, Seong Cheol Min, Santosh Chokkakula, Sol Oh, et al. (+7)
35 [GO] 2023―Jul―08 Identification of alpha-linolenic acid as a broad-spectrum antiviral against zika, dengue, herpes simplex, influenza virus and SARS-CoV-2 infection Yifei Feng, Yan Yang, Shuting Zou, Shuqi Qiu, Hao Yang, Yi Hu, et al. (+4)
36 [GO] 2023―Jun―25 Paxlovid for hospitalized COVID-19 patients with chronic kidney disease Hong Cai, Jiayi Yan, Shang Liu, Ping Li, Li Ding, Yaping Zhan, et al. (+10)
37 [GO] 2023―Jun―23 Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 infection Rafaela Milan Bonotto, Ana Mitrović, Izidor Sosič, Pamela Martinez-Orellana, Federica Dattola, Stanislav Gobec, et al. (+2)
38 [GO] 2023―Jun―15 Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified spike protein and a genetic adjuvant confers lasting mucosal immunity against SARS-CoV-2 Hi Eun Jung, Keun Bon Ku, Byeong Hoon Kang, Jang Hyun Park, Hyeon Cheol Kim, Kyun-Do Kim, Heung Kyu Lee
39 [GO] 2023―Jun―15 Combining virtual screening with cis-/trans-cleavage enzymatic assays effectively reveals broad-spectrum inhibitors that target the main proteases of SARS-CoV-2 and MERS-CoV Yu-Jen Chang, Uyen Nguyen Phuong Le, Jia-Jun Liu, Sin-Rong Li, Shao-Ting Chao, Hsueh-Chou Lai, et al. (+4)
40 [GO] 2023―May―18 SARS-CoV-2 induces cardiomyocyte apoptosis and inflammation but can be ameliorated by ACE inhibitor Captopril Xiaohan Huang, Wenxia Fan, Jing Sun, Jiaqing Yang, Yanjun Zhang, Qian Wang, et al. (+9)
41 [GO] 2023―Apr―20 Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants Junhyung Cho, Younmin Shin, Jeong-Sun Yang, Jun Won Kim, Kyung-Chang Kim, Joo-Yeon Lee
42 [GO] 2023―Apr―18 Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2 Yihua Li, Kun Wang, Hongmin Sun, Shuo Wu, Huiqiang Wang, Yuanyuan Shi, et al. (+11)
43 [GO] 2023―Apr―15 Longitudinal analyses using 18F-Fluorodeoxyglucose positron emission tomography with computed tomography as a measure of COVID-19 severity in the aged, young, and humanized ACE2 SARS-CoV-2 hamster models Yu Cong, Ji Hyun Lee, Donna L. Perry, Kurt Cooper, Hui Wang, Saurabh Dixit, et al. (+29)
44 [GO] 2023―Mar―31 The multiple roles of nsp6 in the molecular pathogenesis of SARS-CoV-2 Cody Bills, Xuping Xie, Pei-Yong Shi
45 [GO] 2023―Mar―30 Evaluation of a panel of therapeutic antibody clinical candidates for efficacy against SARS-CoV-2 in Syrian hamsters Yu Cong, Eric M. Mucker, Donna L. Perry, Saurabh Dixit, Erin Kollins, Russ Byrum, et al. (+22)
46 [GO] 2023―Mar―28 Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2 Yujian Yang, Liu Cao, Ming Yan, Jun Zhou, Sidi Yang, Tiefeng Xu, et al. (+10)
47 [GO] 2023―Mar―26 Cellular electrical impedance to profile SARS-CoV-2 fusion inhibitors and to assess the fusogenic potential of spike mutants Emiel Vanhulle, Jordi Doijen, Joren Stroobants, Becky Provinciael, Sam Noppen, Dominique Schols, et al. (+2)
48 [GO] 2023―Mar―20 SARS-CoV-2 Omicron (B.1.1.529) shows minimal neurotropism in a double-humanized mouse model Rubens Prince dos Santos Alves, Ying-Ting Wang, Zbigniew Mikulski, Sara McArdle, Norazizah Shafee, Kristen M. Valentine, et al. (+18)
49 [GO] 2023―Mar―05 Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine Changrui Lu, Yuntao Zhang, Xiaohu Liu, Fujun Hou, Rujie Cai, Zhibin Yu, et al. (+27)
50 [GO] 2023―Mar―02 Cyclic lipopeptides as membrane fusion inhibitors against SARS-CoV-2: New tricks for old dogs Egor V. Shekunov, Polina D. Zlodeeva, Svetlana S. Efimova, Anna A. Muryleva, Vladimir V. Zarubaev, Alexander V. Slita, Olga S. Ostroumova
51 [GO] 2023―Mar―02 Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants Ji Woong Kim, Kyun Heo, Hyun Jung Kim, Youngki Yoo, Hyun-Soo Cho, Hui Jeong Jang, et al. (+13)
52 [GO] 2023―Mar―01 Pinosrtobin from plants and propolis against human coronavirus HCoV-OC43 by modulating host AHR/CYP1A1 pathway and lipid metabolism Liyun Zhao, Liyuan Yao, Rui Chen, Jiani He, Tingting Lin, Silin Qiu, et al. (+3)
53 [GO] 2023―Mar―01 Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides Yue Hu, Yuanmei Zhu, Yanying Yu, Nian Liu, Xiaohui Ju, Qiang Ding, Yuxian He
54 [GO] 2023―Feb―18 CDK4/6 inhibitor palbociclib promotes SARS-CoV-2 cell entry by down-regulating SKP2 dependent ACE2 degradation Yingzi Xiao, Ying Yan, Le Chang, Huimin Ji, Huizhen Sun, Shi Song, et al. (+4)
55 [GO] 2023―Feb―14 Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses Jiajing Li, Yining Wang, Kundan Solanki, Rajat Atre, Marla Lavrijsen, Qiuwei Pan, et al. (+2)
56 [GO] 2023―Feb―03 Nucleolin mediates SARS-CoV-2 replication and viral-induced apoptosis of host cells Vanessa F. Merino, Yu Yan, Alvaro A. Ordonez, C. Korin Bullen, Albert Lee, Harumi Saeki, et al. (+4)
57 [GO] 2023―Jan―20 Development of highly effective LCB1-based lipopeptides targeting the spike receptor-binding motif of SARS-CoV-2 Yuanmei Zhu, Min Li, Nian Liu, Tong Wu, Xuelian Han, Guangyu Zhao, Yuxian He
58 [GO] 2022―Dec―29 “Flavivirus proteases: The viral Achilles heel to prevent future pandemics” Tadahisa Teramoto, Kyung H. Choi, Radhakrishnan Padmanabhan
59 [GO] 2022―Dec―27 Targeting SARS-CoV-2 and host cell receptor interactions Siew Pheng Lim
60 [GO] 2022―Dec―24 A new intracellular targeting motif in the cytoplasmic tail of the spike protein may act as a target to inhibit SARS-CoV-2 assembly Longbo Hu, Yongjie Tang, Lingling Mei, Mengdi Liang, Jinxian Huang, Xufei Wang, et al. (+8)
61 [GO] 2022―Dec―23 Influenza antivirals and their role in pandemic preparedness Jeremy C. Jones, Hui-Ling Yen, Peter Adams, Kimberly Armstrong, Elena A. Govorkova
62 [GO] 2022―Dec―22 Kill or corrupt: Mechanisms of action and drug-resistance of nucleotide analogues against SARS-CoV-2 Ashleigh Shannon, Bruno Canard
63 [GO] 2022―Dec―22 Reverse genetic systems of SARS-CoV-2 for antiviral research Chaitanya Kurhade, Xuping Xie, Pei-Yong Shi
64 [GO] 2022―Dec―21 Intranasal delivery of replicating mRNA encoding hACE2-targeting antibody against SARS-CoV-2 Omicron infection in the hamster Ya-Nan Zhang, Hong-Qing Zhang, Gui-Feng Wang, Zhe-Rui Zhang, Jia-Qi Li, Xiao-Ling Chen, et al. (+9)
65 [GO] 2022―Dec―21 Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug discovery Winston Chiu, Joost Schepers, Thibault Francken, Laura Vangeel, Kayvan Abbasi, Dirk Jochmans, et al. (+6)
66 [GO] 2022―Dec―16 Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model Dylan M. Johnson, Trevor Brasel, Shane Massey, Tania Garron, Michael Grimes, Jeanon Smith, et al. (+5)
67 [GO] 2022―Dec―05 Phenothiazines inhibit SARS-CoV-2 cell entry via a blockade of spike protein binding to neuropilin-1 Mei Hashizume, Ayako Takashima, Chikako Ono, Toru Okamoto, Masaharu Iwasaki
68 [GO] 2022―Dec―01 RBM24 inhibits the translation of SARS-CoV-2 polyproteins by targeting the 5ʹ-untranslated region Yongxuan Yao, Hao Sun, Yingshan Chen, Lingqian Tian, Dan Huang, Canyu Liu, et al. (+6)
69 [GO] 2022―Nov―23 Rapid discovery and classification of inhibitors of coronavirus infection by pseudovirus screen and amplified luminescence proximity homogeneous assay Kwiwan Jeong, JuOae Chang, Sun-mi Park, Jinhee Kim, Sangeun Jeon, Dong Hwan Kim, et al. (+20)
70 [GO] 2022―Nov―21 Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier Aileen Faist, Sebastian Schloer, Angeles Mecate-Zambrano, Josua Janowski, André Schreiber, Yvonne Boergeling, et al. (+23)
71 [GO] 2022―Nov―17 In vitro and in vivo effects of 3-indoleacetonitrile-A potential new broad-spectrum therapeutic agent for SARS-CoV-2 infection Xianfeng Hui, Xiao Yu, Kun Huang, Ting Xu, Lei Cao, Yufei Zhang, et al. (+7)
72 [GO] 2022―Nov―03 Structure and inhibition of SARS-CoV-1 and SARS-CoV-2 main proteases by oral antiviral compound AG7404 Montserrat Fàbrega-Ferrer, Alejandra Herrera-Morandé, Sara Muriel-Goñi, Julia Pérez-Saavedra, Paula Bueno, Victoria Castro, et al. (+3)
73 [GO] 2022―Oct―31 Topoisomerase 3b is dispensable for replication of a positive-sense RNA virus--murine coronavirus Tianyi Zhang, Shuaikun Su, Valerie Altouma, Xingliang Zhu, Yutong Xue, Weiping Shen, et al. (+2)
74 [GO] 2022―Oct―30 In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2 Weijuan Shang, Wenhao Dai, Cheng Yao, Ling Xu, Xiangming Tao, Haixia Su, et al. (+8)
75 [GO] 2022―Oct―29 Geneticin shows selective antiviral activity against SARS-CoV-2 by interfering with programmed -1 ribosomal frameshifting Carmine Varricchio, Gregory Mathez, Trestan Pillonel, Claire Bertelli, Laurent Kaiser, Caroline Tapparel, et al. (+2)
76 [GO] 2022―Oct―17 Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides Yuanmei Zhu, Yue Hu, Nian Liu, Huihui Chong, Yuxian He
77 [GO] 2022―Oct―15 Astersaponin I from Aster koraiensis is a natural viral fusion blocker that inhibit the infection of SARS-CoV-2 variants and syncytium formation Tai Young Kim, Ji-Young Kim, Hak Cheol Kwon, Sangeun Jeon, Sol ji Lee, Haejin Jung, et al. (+3)
78 [GO] 2022―Oct―06 Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice Ju Hwan Jeong, Santosh Chokkakula, Seong Cheol Min, Beom Kyu Kim, Won-Suk Choi, Sol Oh, et al. (+9)
79 [GO] 2022―Oct―05 Generation of a VeroE6 Pgp gene knock out cell line and its use in SARS-CoV-2 antiviral study Yuao Zhu, Joe Binder, Irina Yurgelonis, Devendra Rai, Sarah Lazarro, Chester Costales, et al. (+6)
80 [GO] 2022―Sep―23 Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CLpro Ling Ma, Quanjie Li, Yongli Xie, Dongrong Yi, Saisai Guo, Fei Guo, et al. (+3)
81 [GO] 2022―Aug―28 Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19 James F. Demarest, Maryline Kienle, RuthMabel Boytz, Mary Ayres, Eun Jung Kim, Justin J. Patten, et al. (+7)
82 [GO] 2022―Aug―17 Punicalagin as an allosteric NSP13 helicase inhibitor potently suppresses SARS-CoV-2 replication in vitro Lian Lu, Yun Peng, Huiqiao Yao, Yanqun Wang, Jinyu Li, Yang Yang, Zhonghui Lin
83 [GO] 2022―Jul―31 Rational design of AAVrh10-vectored ACE2 functional domain to broadly block the cell entry of SARS-CoV-2 variants Minchao Li, Jiaoshan Chen, Yajie Liu, Jin Zhao, Yanjun Li, Yunqi Hu, et al. (+5)
84 [GO] 2022―Jul―11 Allosteric inhibitors of the main protease of SARS-CoV-2 Subodh Kumar Samrat, Jimin Xu, Xuping Xie, Eleonora Gianti, Haiying Chen, Jing Zou, et al. (+8)
85 [GO] 2022―Jul―04 Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2 Hirofumi Ohashi, Takayuki Hishiki, Daisuke Akazawa, Kwang Su Kim, Joohyeon Woo, Kaho Shionoya, et al. (+17)
86 [GO] 2022―Jul―04 Hydroxypropyl-beta-cyclodextrin (HP-BCD) inhibits SARS-CoV-2 replication and virus-induced inflammatory cytokines Bruno Braz Bezerra, Gustavo Peixoto Duarte da Silva, Sharton Vinicius Antunes Coelho, Isadora Alonso Correa, Marcos Romario Matos de Souza, Keylla Vitória Gomes Macedo, et al. (+6)
87 [GO] 2022―Jun―29 Inhibition of a broad range of SARS-CoV-2 variants by antiviral phytochemicals in hACE2 mice Eun-Ha Kim, Ba Wool Lee, Byeol Ryu, Hyo Moon Cho, Se-Mi Kim, Seung-Gyu Jang, et al. (+6)
88 [GO] 2022―Jun―27 A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera Chotiwat Seephetdee, Kanit Bhukhai, Nattawut Buasri, Puttipatch Leelukkanaveera, Pat Lerdwattanasombat, Suwimon Manopwisedjaroen, et al. (+7)
89 [GO] 2022―Jun―21 Numb-associated kinases are required for SARS-CoV-2 infection and are cellular targets for antiviral strategies Marwah Karim, Sirle Saul, Luca Ghita, Malaya Kumar Sahoo, Chengjin Ye, Nishank Bhalla, et al. (+12)
90 [GO] 2022―Jun―19 Bergamottin, a bioactive component of bergamot, inhibits SARS-CoV-2 infection in golden Syrian hamsters Minmin Zhou, Yang Liu, Junyuan Cao, Siqi Dong, Yuxia Hou, Yan Yu, et al. (+7)
91 [GO] 2022―Jun―16 Identification of potent inhibitors of arenavirus and SARS-CoV-2 exoribonucleases by fluorescence polarization assay Sergio Hernández, Mikael Feracci, Carolina Trajano De Jesus, Priscila El Kazzi, Rafik Kaci, Laura Garlatti, et al. (+10)
92 [GO] 2022―Jun―10 Conserved coronavirus proteins as targets of broad-spectrum antivirals Cleber C. Melo-Filho, Tesia Bobrowski, Holli-Joi Martin, Zoe Sessions, Konstantin Popov, Nathaniel J. Moorman, et al. (+3)
93 [GO] 2022―Jun―07 Discovery of novel SARS-CoV-2 inhibitors targeting the main protease Mpro by virtual screenings and hit optimization Beatrice Mercorelli, Jenny Desantis, Marta Celegato, Alessandro Bazzacco, Lydia Siragusa, Paolo Benedetti, et al. (+5)
94 [GO] 2022―May―28 A novel high-throughput single B-cell cloning platform for isolation and characterization of high-affinity and potent SARS-CoV-2 neutralizing antibodies Paritosh Prashar, Sonali Swain, Nisha Adhikari, Punit Aryan, Anupama Singh, Mohit Kwatra, Prabhakar B
95 [GO] 2022―May―21 Animal models for studying coronavirus infections and developing antiviral agents and vaccines Qisheng Lin, Chunni Lu, Yuqi Hong, Runfeng Li, Jinding Chen, Weisan Chen, Jianxin Chen
96 [GO] 2022―May―19 Immunodetection assays for the quantification of seasonal common cold coronaviruses OC43, NL63, or 229E infection confirm nirmatrelvir as broad coronavirus inhibitor Tatjana Weil, Jan Lawrenz, Alina Seidel, Jan Münch, Janis A. Müller
97 [GO] 2022―May―19 Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening Anu Roy, Yousef M. Alhammad, Peter McDonald, David K. Johnson, Junlin Zhuo, Sarah Wazir, et al. (+4)
98 [GO] 2022―May―18 SARS-CoV-2 Permissive glioblastoma cell line for high throughput antiviral screening Emiel Vanhulle, Joren Stroobants, Becky Provinciael, Anita Camps, Sam Noppen, Piet Maes, Kurt Vermeire
99 [GO] 2022―May―07 Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins Stephen Findlay-Wilson, Linda Easterbrook, Sandra Smith, Neville Pope, Gareth Humphries, Holger Schuhmann, et al. (+15)
100 [GO] 2022―May―05 Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection Jared Pitts, Darius Babusis, Meghan S. Vermillion, Raju Subramanian, Kim Barrett, Diane Lye, et al. (+14)
101 [GO] 2022―Apr―04 HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect Caroline S. Foo, Rana Abdelnabi, Suzanne J.F. Kaptein, Xin Zhang, Sebastiaan ter Horst, Raf Mols, et al. (+20)
102 [GO] 2022―Mar―24 Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants Mikako Ueno, Naoko Iwata-Yoshikawa, Akihito Matsunaga, Tadashi Okamura, Sho Saito, Shinobu Ashida, et al. (+17)
103 [GO] 2022―Mar―13 Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain Guan-Chun Lai, Tai-Ling Chao, Shiau-Yu Lin, Han-Chieh Kao, Ya-Min Tsai, De-Chao Lu, et al. (+3)
104 [GO] 2022―Mar―11 Novel antiviral activity of PAD inhibitors against human beta-coronaviruses HCoV-OC43 and SARS-CoV-2 Selina Pasquero, Francesca Gugliesi, Gloria Griffante, Valentina Dell’Oste, Matteo Biolatti, Camilla Albano, et al. (+6)
105 [GO] 2022―Mar―09 Label-free duplex SAMDI-MS screen reveals novel SARS-CoV-2 3CLpro inhibitors. M.D. Scholle, P. O'Kane, S. Dib, Z.A. Gurard-Levin
106 [GO] 2022―Mar―09 A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors K.Y. Chen, T. Krischuns, L.Ortega Varga, E. Harigua-Souiai, S. Paisant, A. Zettor, et al. (+11)
107 [GO] 2022―Mar―07 Establishment of a stable SARS-CoV-2 replicon system for application in high-throughput screening Tomohisa Tanaka, Akatsuki Saito, Tatsuya Suzuki, Yoichi Miyamoto, Kazuo Takayama, Toru Okamoto, Kohji Moriishi
108 [GO] 2022―Feb―28 ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern Tsung-I Tsai, Jahan S. Khalili, Mark Gilchrist, Andrew B. Waight, Daniella Cohen, Shi Zhuo, et al. (+6)
109 [GO] 2022―Jan―29 5-Iodotubercidin inhibits SARS-CoV-2 RNA synthesis Jianyuan Zhao, Qian Liu, Dongrong Yi, Quanjie Li, SaiSai Guo, Ling Ma, et al. (+7)
110 [GO] 2022―Jan―24 Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern Laura Vangeel, Winston Chiu, Steven De Jonghe, Piet Maes, Bram Slechten, Joren Raymenants, et al. (+4)
111 [GO] 2022―Jan―21 The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters Rana Abdelnabi, Caroline S. Foo, Xin Zhang, Viktor Lemmens, Piet Maes, Bram Slechten, et al. (+5)
112 [GO] 2022―Jan―13 Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis Daniele Focosi, Fabrizio Maggi, Scott McConnell, Arturo Casadevall
113 [GO] 2022―Jan―13 Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2 Brandi N. Williamson, Lizzette Pérez-Pérez, Benjamin Schwarz, Friederike Feldmann, Myndi G. Holbrook, Manmeet Singh, et al. (+13)
114 [GO] 2021―Dec―29 S-adenosylmethionine-dependent methyltransferase inhibitor DZNep blocks transcription and translation of SARS-CoV-2 genome with a low tendency to select for drug-resistant viral variants Ram Kumar, Nitin Khandelwal, Yogesh Chander, Himanshu Nagori, Assim Verma, Aditya Barua, et al. (+6)
115 [GO] 2021―Dec―18 COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment - Meeting report from an isirv-WHO virtual conference Jennifer L. McKimm-Breschkin, Alan J. Hay, Bin Cao, Rebecca J. Cox, Jake Dunning, Ann C. Moen, et al. (+3)
116 [GO] 2021―Nov―24 Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model Maxime Cochin, Franck Touret, Jean-Sélim Driouich, Gregory Moureau, Paul-Rémi Petit, Caroline Laprie, et al. (+3)
117 [GO] 2021―Nov―18 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors Jianyuan Zhao, Guoning Zhang, Yongxin Zhang, Dongrong Yi, Quanjie Li, Ling Ma, et al. (+8)
118 [GO] 2021―Nov―10 Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein Hristo L. Svilenov, Julia Sacherl, Alwin Reiter, Lisa S. Wolff, Cho-Chin Cheng, Marcel Stern, et al. (+10)
119 [GO] 2021―Nov―08 Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies Hongyu Qiu, Xin-Yong Yuan, Teresa Cabral, Kathy Manguiat, Alyssia Robinson, Heidi Wood, et al. (+8)
120 [GO] 2021―Oct―21 Inhibition of endocytosis of porcine reproductive and respiratory syndrome virus by rottlerin and its potential prophylactic administration in piglets Yeong-Lim Kang, Changin Oh, So-Hyun Ahn, Jong-Chul Choi, Hwi-Yeon Choi, Sang-Won Lee, et al. (+4)
121 [GO] 2021―Oct―08 SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad neutralizing activity and No evidence of antibody-dependent enhancement Ying-Ting Wang, Robert D. Allen, Kenneth Kim, Norazizah Shafee, Andrew J. Gonzalez, Michael N. Nguyen, et al. (+9)
122 [GO] 2021―Oct―07 A fluorescence-based, gain-of-signal, live cell system to evaluate SARS-CoV-2 main protease inhibition Rama Dey-Rao, George R. Smith, Uddhav Timilsina, Zackary Falls, Ram Samudrala, Spyridon Stavrou, Thomas Melendy
123 [GO] 2021―Aug―24 Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target Isabel García-Dorival, Miguel Ángel Cuesta-Geijo, Lucía Barrado-Gil, Inmaculada Galindo, Urtzi Garaigorta, Jesús Urquiza, et al. (+6)
124 [GO] 2021―Aug―09 Polyphenylene carboxymethylene (PPCM) microbicide repurposed as antiviral against SARS-CoV-2. Proof of concept in primary human undifferentiated epithelial cells Olivier Escaffre, Alexander N. Freiberg
125 [GO] 2021―Aug―08 A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency Adam Leach, F. Tudor Ilca, Zulaikha Akbar, Mathieu Ferrari, Emma M. Bentley, Giada Mattiuzzo, et al. (+4)
126 [GO] 2021―Jul―23 Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase Renata Kasprzyk, Tomasz J. Spiewla, Miroslaw Smietanski, Sebastian Golojuch, Laura Vangeel, Steven De Jonghe, et al. (+4)
127 [GO] 2021―Jul―12 Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2 Franck Touret, Jean-Sélim Driouich, Maxime Cochin, Paul Rémi Petit, Magali Gilles, Karine Barthélémy, et al. (+6)
128 [GO] 2021―Jul―08 A mouse model of lethal respiratory dysfunction for SARS-CoV-2 infection Esther S. Gan, Ayesa Syenina, Martin Linster, Benson Ng, Summer L. Zhang, Satoru Watanabe, et al. (+4)
129 [GO] 2021―Jun―26 A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents Thuc Nguyen Dan Do, Kim Donckers, Laura Vangeel, Arnab K. Chatterjee, Philippe A. Gallay, Michael D. Bobardt, et al. (+5)
130 [GO] 2021―Jun―19 Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo Trinayan Kashyap, Jackelyn Murray, Christopher J. Walker, Hua Chang, Sharon Tamir, Bing Hou, et al. (+4)
131 [GO] 2021―May―16 Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro Jeremy R.A. Paull, Graham P. Heery, Michael D. Bobardt, Alex Castellarnau, Carolyn A. Luscombe, Jacinth K. Fairley, Philippe A. Gallay
132 [GO] 2021―Apr―21 A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase Jianyuan Zhao, SaiSai Guo, Dongrong Yi, Quanjie Li, Ling Ma, Yongxin Zhang, et al. (+7)
133 [GO] 2021―Apr―17 Discovery of Chebulagic Acid and Punicalagin as Novel Allosteric Inhibitors of SARS-CoV-2 3CLpro Ruikun Du, Laura Cooper, Zinuo Chen, Hyun Lee, Lijun Rong, Qinghua Cui
134 [GO] 2021―Mar―27 Proteomic Analysis Identifies the RNA Helicase DDX3X as a Host Target Against SARS-CoV-2 Infection Fabiola Ciccosanti, Martina Di Rienzo, Alessandra Romagnoli, Francesca Colavita, Giulia Refolo, Concetta Castilletti, et al. (+8)
135 [GO] 2021―Mar―11 Emetine suppresses SARS-CoV-2 replication by inhibiting interaction of viral mRNA with eIF4E Ram Kumar, Mohammad Afsar, Nitin Khandelwal, Yogesh Chander, Thachamvally Riyesh, Ramesh Kumar Dedar, et al. (+6)
136 [GO] 2021―Mar―11 Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors Mario Milani, Manuela Donalisio, Rafaela Milan Bonotto, Edoardo Schneider, Irene Arduino, Francesco Boni, et al. (+3)
137 [GO] 2021―Feb―06 Genetic Conservation of SARS-CoV-2 RNA Replication Complex in Globally Circulating Isolates and Recently Emerged Variants from Humans and Minks Suggests Minimal Pre-Existing Resistance to Remdesivir Ross Martin, Jiani Li, Aiyippa Parvangada, Jason Perry, Tomas Cihlar, Hongmei Mo, et al. (+2)
138 [GO] 2021―Jan―27 Dual Inhibition of SARS-CoV-2 and Human Rhinovirus with Protease Inhibitors in Clinical Development Cheng Liu, Sandro Boland, Michael D. Scholle, Dorothee Bardiot, Arnaud Marchand, Patrick Chaltin, et al. (+7)
139 [GO] 2021―Jan―13 Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system Qingyuan Zhu, Yaling Zhang, Li Wang, Xiangyu Yao, Daitze Wu, Junjun Cheng, et al. (+4)
140 [GO] 2021―Jan―08 The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo Christin Müller, Wiebke Obermann, Nadja Karl, Hans-Guido Wendel, Gaspar Taroncher-Oldenburg, Stephan Pleschka, et al. (+3)
141 [GO] 2020―Dec―10 Antiviral activity against Middle East Respiratory Syndrome Coronavirus by Montelukast, an anti-asthma drug Hanjie Jonathan Gan, Amaravadhi Harikishore, Jihye Lee, Sangeun Jeon, Sreekanth Rajan, Ming Wei Chen, et al. (+3)
142 [GO] 2020―Nov―25 Ionophore antibiotic X-206 is a potent inhibitor of SARS-CoV-2 infection in vitro Esben B. Svenningsen, Jacob Thyrsted, Julia Blay-Cadanet, Han Liu, Shaoquan Lin, Jaime Moyano Villameriel, et al. (+5)
143 [GO] 2020―Nov―17 A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2 Yang Zhang, Wuhui Song, Shuiye Chen, Zhenghong Yuan, Zhigang Yi
144 [GO] 2020―Oct―19 Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes Seong Woo Choi, Jin Soo Shin, Soon-Jung Park, Eunhye Jung, Yun-Gwi Park, Jiho Lee, et al. (+7)
145 [GO] 2020―Sep―19 Cryptotanshinone Protects Porcine Alveolar Macrophages from Infection with Porcine Reproductive and Respiratory Syndrome Virus Chang Huang, Jiaqi Zhu, Ling Wang, Alexander Chu, Yexuan Yin, Kaneha Vali, et al. (+2)
146 [GO] 2020―Sep―07 Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses Sirin Theerawatanasirikul, Chih Jung Kuo, Nanthawan Phecharat, Jullada Chootip, Chalermpol Lekcharoensuk, Porntippa Lekcharoensuk
147 [GO] 2020―Sep―06 Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry Zachary A. Gurard-Levin, Cheng Liu, Andreas Jekle, Ruchika Jaisinghani, Suping Ren, Koen Vandyck, et al. (+9)
148 [GO] 2020―Jul―30 The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro Mika Okamoto, Masaaki Toyama, Masanori Baba
149 [GO] 2020―Jul―29 An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection Carina Conzelmann, Andrea Gilg, Rüdiger Groß, Desiree Schütz, Nico Preising, Ludger Ständker, et al. (+7)
150 [GO] 2020―Jul―15 In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2 Andrés Pizzorno, Blandine Padey, Julia Dubois, Thomas Julien, Aurélien Traversier, Victoria Dulière, et al. (+4)
151 [GO] 2020―Jul―15 Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors Pierre Gallian, Boris Pastorino, Pascal Morel, Jacques Chiaroni, Laetitia Ninove, Xavier de Lamballerie
152 [GO] 2020―Jul―10 Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection Nicolas Venisse, Gilles Peytavin, Stephane Bouchet, Marie-Claude Gagnieu, Rodolphe Garraffo, Romain Guilhaumou, Caroline Solas
153 [GO] 2020―Jul―10 Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions So Young Kim, Weihua Jin, Amika Sood, David W. Montgomery, Oliver C. Grant, Mark M. Fuster, et al. (+5)
154 [GO] 2020―Jul―10 Immunoglobulin fragment F(ab’)2 against RBD potently neutralizes SARS-CoV-2 in vitro Xiaoyan Pan, Pengfei Zhou, Tiejiong Fan, Yan Wu, Jing Zhang, Xiaoyue Shi, et al. (+9)
155 [GO] 2020―Jun―19 The influence of interferon-lambda on restricting Middle East Respiratory Syndrome Coronavirus replication in the respiratory epithelium Yung Jin Jeon, Chan Hee Gil, Ara Jo, Jina Won, Sujin Kim, Hyun Jik Kim
156 [GO] 2020―Jun―18 A Library of Nucleotide Analogues Terminate RNA Synthesis Catalyzed by Polymerases of Coronaviruses that Cause SARS and COVID-19 Steffen Jockusch, Chuanjuan Tao, Xiaoxu Li, Thomas K. Anderson, Minchen Chien, Shiv Kumar, et al. (+3)
157 [GO] 2020―May―13 Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2 Wanbo Tai, Xiujuan Zhang, Yuxian He, Shibo Jiang, Lanying Du
158 [GO] 2020―Apr―29 Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection Emily Mantlo, Natalya Bukreyeva, Junki Maruyama, Slobodan Paessler, Cheng Huang
159 [GO] 2020―Apr―21 Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses Mike Bray, Craig Rayner, François Noël, David Jans, Kylie Wagstaff
160 [GO] 2020―Apr―10 Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites Ashleigh Shannon, Nhung Thi-Tuyet Le, Barbara Selisko, Cecilia Eydoux, Karine Alvarez, Jean-Claude Guillemot, et al. (+4)
161 [GO] 2020―Apr―07 Type 1 interferons as a potential treatment against COVID-19 Erwan Sallard, François-Xavier Lescure, Yazdan Yazdanpanah, France Mentre, Nathan Peiffer-Smadja
162 [GO] 2020―Apr―06 Coronavirus membrane fusion mechanism offers as a potential target for antiviral development Tiffany Tang, Miya Bidon, Javier A. Jaimes, Gary R. Whittaker, Susan Daniel
163 [GO] 2020―Apr―03 The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro Leon Caly, Julian D. Druce, Mike G. Catton, David A. Jans, Kylie M. Wagstaff
164 [GO] 2020―Apr―03 Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro Ka-Tim Choy, Alvina Yin-Lam Wong, Prathanporn Kaewpreedee, Sin-Fun Sia, Dongdong Chen, Kenrie Pui Yan Hui, et al. (+6)
165 [GO] 2020―Mar―06 Of chloroquine and COVID-19 Franck Touret, Xavier de Lamballerie
166 [GO] 2020―Mar―01 A potential role for integrins in host cell entry by SARS-CoV-2 Christian JA Sigrist, Alan Bridge, Philippe Le Mercier
167 [GO] 2020―Feb―27 Efficacy of anti-influenza immunoglobulin (FLU-IGIV) in ferrets and mice infected with 2009 pandemic influenza virus Hongyu Qiu, Hanne Andersen, E. Bart Tarbet, F. Salih Muhammad, Trevor Carnelley, Russell Pronyk, et al. (+2)
168 [GO] 2020―Feb―10 The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade B. Coutard, C. Valle, X. de Lamballerie, B. Canard, N.G. Seidah, E. Decroly
 [1] 

168 Results       Page 1



[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.021 sec